Literature DB >> 2405610

Adenosine or adenosine triphosphate for supraventricular tachycardias? Comparative double-blind randomized study in patients with spontaneous or inducible arrhythmias.

A C Rankin1, K G Oldroyd, E Chong, J W Dow, A P Rae, S M Cobbe.   

Abstract

The effects of intravenous adenosine and adenosine triphosphate (ATP) were studied in a double-blind randomized study during 68 episodes of supraventricular tachycardia in 39 patients. Adenosine restored sinus rhythm in 20 patients (25 of 27 episodes) and produced atrioventricular block to reveal atrial arrhythmias in nine. ATP restored sinus rhythm in 17 patients (22 of 25 episodes) and revealed atrial tachyarrhythmias in six. In patients receiving both compounds, the effective dosage of adenosine was 3.8 mg and of ATP it was 6.6 mg (p less than 0.05), suggesting molar equipotency. Transient side effects were common, occurring in 81% of episodes with adenosine and in 94% with ATP. Symptom scores (0 to 10) were not significantly different (median score for adenosine was 5, for ATP it was 6). Adenosine and ATP were equally effective for the diagnosis and treatment of supraventricular tachycardias and the incidence and severity of side effects were similar. Adenosine has the advantage of being more stable.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405610     DOI: 10.1016/s0002-8703(05)80022-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  11 in total

1.  Dose and rate-dependent effects of adenosine on atrial action potential duration in humans.

Authors:  J Tebbenjohanns; B Schumacher; D Pfeiffer; W Jung; B Lüderitz
Journal:  J Interv Card Electrophysiol       Date:  1997-02       Impact factor: 1.900

Review 2.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

Review 3.  Adenosine. An evaluation of its use in cardiac diagnostic procedures, and in the treatment of paroxysmal supraventricular tachycardia.

Authors:  D Faulds; P Chrisp; M M Buckley
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Prehospital use of adenosine by ambulance services in the Netherlands: Daily practice, literature overview and practical recommendations.

Authors:  R Adams; V Bon
Journal:  Neth Heart J       Date:  2003-05       Impact factor: 2.380

Review 5.  Adenosine triphosphate: established and potential clinical applications.

Authors:  H J Agteresch; P C Dagnelie; J W van den Berg; J H Wilson
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

6.  Interesting electrophysiological findings in a patient with coexistence of atrial tachycardia originating from coronary sinus and slow-fast atrioventricular nodal reentrant tachycardia.

Authors:  Kyoichiro Yazaki; Kenji Enta; Shohei Kataoka; Mitsuru Kahata; Asako Kumagai; Koji Inoue; Hiroshi Koganei; Masato Otsuka; Yasuhiro Ishii
Journal:  J Cardiol Cases       Date:  2016-11-22

7.  Evidence for a cooperation between adenosine A2 receptors and beta 1-adrenoceptors on cardiac automaticity in the isolated right ventricle of the rat.

Authors:  J Hernandez; F Pinto; M A Figueira; J A Riberio
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

8.  Involvement of alpha-adrenoceptors in the excitatory effect of the A2 adenosine receptors agonist 5'-N-ethylcarboxamidoadenosine (NECA) on cardiac automaticity in the isolated right ventricle of the rat.

Authors:  J Hernández; F Pinto; J A Ribeiro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

Review 9.  The therapeutic and diagnostic cardiac electrophysiological uses of adenosine.

Authors:  A D Malcolm; C J Garratt; A J Camm
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

10.  Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients.

Authors:  Sandra Beijer; Eric A R Gielisse; Pierre S Hupperets; Ben E E M van den Borne; Marieke van den Beuken-van Everdingen; Marten R Nijziel; Arjen M J van Henten; Pieter C Dagnelie
Journal:  Invest New Drugs       Date:  2007-09-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.